Anavex Reports Animal Study Results as Lead Alzheimer’s Compound Approaches Phase 1 Clinical Trials

Geneva, Switzerland — May 4, 2010 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) is pleased to report promising results from animal studies with ANAVEX 2-73, the company’s lead compound for the treatment and modification of Alzheimer’s disease.ANAVEX 2-73 is the first of a new class of drugs that target mitochondrial dysfunction thought to be…